Multiple Myeloma Research Consortium names MDS Pharma Services as preferred CRO

Philadelphia, PA – Drug development and discovery provider, MDS Pharma Services, has been selected as the preferred contract research organization (CRO) of the Multiple Myeloma Research Consortium. The company says it will manage multiple pre-clinical and clinical research efforts for the consortium, including data management related to the its tissue collection program.

An incurable but treatable disease, multiple myeloma is a cancer of the plasma cell and the second most prevalent blood cancer after non-Hodgkin’s lymphoma.

The Multiple Myeloma Research Consortium is comprised of seven member institutions: Dana-Farber Cancer Institute, H Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, University Health Network (Princess Margaret Hospital), Emory University’s Winship Cancer Institute, University of Chicago and St. Vincent’s Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York.